MT4 Mixed Treatment Comparisons Using Aggregate- and individual-Participant Level Data: An Efficient Use of Evidence for Cost-Effectiveness Modelling  by Saramago, P. et al.
ket access as well as potentially leading to significant price reductions. What do
these changes mean for the industry? What are the main challenges and opportu-
nities for companies and how can they best adapt? Many questions remain to be
determined. Yet AMNOG sets the scene for a new Market access process in Ger-
many, for which challenges can be foreseen. The industry will need to acquire new
skills to interact with national Market access stakeholders, develop internal effi-
cient processes to compile Benefit Dossiers, adapt the European launch sequence
as well as investigate new Market access strategies, for example targeting sub-
target population groups to demonstrate higher additional benefit or leveraging
Phase IV data. CONCLUSIONS: Industry needs to prepare itself for developing their
launch and commercial strategies in Germany as Germany is a key market from
revenue, price referencing and credibility perspective.
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OBJECTIVES: Spending on prescription drugs in key OECD countries has increased
by 50% or more in the last ten years, raising questions about overall system sus-
tainability. The study analyses possible reasons for differences in prices and vol-
umes consumed across key OECD countries, taking into account national differ-
ences in pharmaceutical policy and regulatory mechanisms.METHODS: Panel data
modelling is used to investigate the effect of pharmaceutical pricing and reim-
bursement regulations, drug promotion, drug use, and competition on price levels.
Data are from IMS Health and the US Federal Supply Schedule and include top-50
selling on patent and generic prescription drugs used in the study countries. Reg-
ulatory variables are included as dummy variables in the model. RESULTS: Prelim-
inary results suggest that: a) cross-country price comparisons are only meaningful
if the right prices are compared in each case. Here, we demonstrate how significant
price differences are when ex-factory prices are compared and how these differ-
ences narrow down significantly when public prices are compared across countries;
b) It seems that price differences of originator brands between the US and Europe
have been exaggerated; generic prices are very often significantly lower in the US
than in other countries; c) Cross-country public price differences and cross-country
ex-factory price differences are not the same across the study countries; d) Off-
patent originator brands account for a significant proportion of the price variation
between US and the other study countries; e) Pricing regulation accounts for a
considerable proportion of the variation in prices across the study countries; and f)
Distribution and taxation can contribute significantly to the total cost of prescrip-
tion medicines that health insurers pay. CONCLUSIONS: Price differences are sig-
nificant when ex-factory prices are compared but are significantly reduced when
public prices are compared across countries. Regulation, distribution, and taxes are
key contributors to the total cost of medicines paid by insurers.
PODIUM SESSION II:
MIXED TREATMENT COMPARISONS MATURE, IN ABSENCE OF SUFFICIENT
HEAD-TO-HEAD COMPARISONS
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OBJECTIVES: Bayesian network meta-analyses incorporate prior distributions
(“priors”) that are updated with new evidence to generate posterior distributions.
The use of uninformative (vague) priors minimizes potential biases and promotes
transparency. Guideline developers have recommended values for uninformative
priors for binary outcomes. For continuous outcomes, the choice of priors is scale-
dependent. In networks with heterogeneity and few studies, a more informed prior
for estimation of between-studies standard deviation () is justifiable, yet may
impose subjectivity. Using a network meta-analysis of seven studies estimating
the efficacy of three renal transplant immunosuppressants (tacrolimus, cyclospo-
rine and belatacept), we estimated the impact of varying priors for  to the relative
effect sizes. METHODS: We established a clinically-plausible range for an uninfor-
mative prior distribution of . We then derived estimates for the indirect compar-
ison of belatacept and tacrolimus expressed as true mean difference (TMD) in renal
function, expressed as glomerular filtration rate (GFR; mL/min/1.73m2); 95% cred-
ible intervals (CrI); and model fit (residual deviance and deviance information cri-
terion). We conducted sensitivity analyses using more informed priors: half the
uninformative range; a data-driven approach; half the data-driven range; and, as
an extreme, a fixed-effect model (  0). RESULTS: Using the uninformative uni-
form prior, U(0,20), the estimated TMD in GFR was 9.84 higher for belatacept than
tacrolimus. This had the best model fit and the widest 95% CrI (1.97, 20.51). As the
upper bound of the prior distribution was restricted, the 95% CrIs narrowed yet the
model fit degraded. The point estimate was stable. The narrowest informed prior
was U(0,3) (TMD 9.84; 95% CrI 4.89, 15.90).CONCLUSIONS: In this analysis, the point
estimates for TMD in GFR consistently favored belatacept, yet the CrIs and model fit
were affected by the choice of prior for . Given the subjectivity in selecting priors
for continuous outcomes, transparent reporting is essential.
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OBJECTIVES: Each of the tumour necrosis factor alpha antagonists (anti-TNF-)
available to treat rheumatoid arthritis have demonstrated considerable efficacy in
placebo controlled trials, but few head-to-head comparisons exist to date. This
work estimates the relative efficacy among licensed anti-TNFs and highlights the
advantages of continuous outcome measures in mixed treatment comparison
models. METHODS: Relative efficacy was estimated using Bayesian mixed treat-
ment comparison (MTC) models. Three different outcome measures were used;
Risk ratios of achieving an ACR20 and ACR50 response (binomial outcomes) and the
percentage improvement in HAQ score (continuous outcome). Five anti-TNF- an-
tagonists were included in the analysis; adalimumab, infliximab, etanercept, goli-
mumab and certolizumab. RESULTS: All anti-TNF agents show a significant im-
provement over placebo across all outcome measures. The HAQ model outcomes
provide evidence that all anti-TNF agents show improvement over infliximab. This
effect is not found with the ACR outcomes for adalimumab and golimumab. Fur-
thermore, the HAQ model indicates a superiority of etanercept over adalimumab.
The evidence of certolizumab pegol providing improvement over golimumab,
which can be found in the ACR outcomes, is not apparent in the HAQ outcomes.
CONCLUSIONS: Continuous outcome measures make better use of the complete
data than binomial measures and are therefore more sensitive to change. The
results suggest that it may be the case, in mixed treatment comparison models,
where the essence lies in detecting differences, a continuous outcome measure is
more appropriate. Its enhanced sensitivity to change increases the power of the
model to detect differences among treatments. The HAQ multiplier provides one
such measure, but others exist.
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OBJECTIVES: Model fit in Bayesian mixed treatment comparisons (MTC) is often
assessed by the deviance information criterion (DIC). In some cases DIC is not
conclusive. Our aim was to compare DIC with an alternative approach: formal
Bayesian model comparison by estimating the posterior distribution over the
model space. METHODS: DIC is a criterion which combines posterior mean of the
deviance and deviance of posterior means. Models with lower DIC should be pre-
ferred, however if the difference in DICs is small the decision should not be based
solely on DIC. Marginal data density (MDD) expresses probability of observing given
dataset. Decision rule based on Bayesian model comparison is that the model with
highest a posteriori probability should be chosen. Data from few systematic reviews
indexed in Pubmed were extracted in order to find MTC datasets for which DICs for
fixed (FEM) and random effects models (REM) are very similar. Two continuous
variables datasets were chosen. Posterior distributions and DICs were estimated in
WinBugs. The Newton-Raftery estimator of MDD was implemented in Java, to-
gether with the Gibbs sampler. In both cases, in which DIC was not conclusive, two
a priori structures over the model space were assumed: an uniform distribution and
one penalizing the models for the excessive number of parameters. RESULTS: In
the first dataset difference in DICs was 1.3 (in favor REM), in the second dataset this
difference was 2,0 (in favor FEM). In both cases REM turned out to have a higher
value of MDD. Although a priori odds ratio was around 100:1 for FEM, the posterior
distribution was in every case close to have probability of one (0.9999) for the REM.
CONCLUSIONS: Decision about model selection should include tools of formal
model comparison, as conclusions coming from it are always interpretable and
coherent within Bayesian inference.
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OBJECTIVES: Cost-effectiveness analysis must use all relevant sources of evi-
dence to inform reimbursement decisions. Mixed treatment comparisons (MTC)
extends the traditional pair-wise meta-analytic framework to facilitate the syn-
thesis of information on more than two interventions. While most MTCs use
aggregate data (AD), a proportion of the evidence base might be available at the
individual level (IPD). This paper develops novel statistical models aimed to
fully exploit the existing data, regardless of the format (i.e. AD or IPD).
METHODS: We develop a series of novel Bayesian statistical MTC models to allow
for the simultaneous synthesis of IPD and AD, while considering study and indi-
vidual level covariates, and use these to inform a decision model. RESULTS: The
effectiveness of home safety education and the provision of functioning smoke
alarms (binary outcome – Yes/No) for the prevention of childhood injuries in the
household was used as a motivating example. Case study included 20 trials (11 AD,
9 IPD), summing up to 11,500 participants. Seven strategies were defined and a
network of evidence was constructed. Irrespective of the evidence format used, all
models which did not consider information on covariate(s) showed equivalent
results, i.e. more intensive interventions (providing education, equipment (with
fitting) and home inspection) were more effective (OR vs usual care of 4.5 (95%
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credible interval: 1.4 to 14.8). Results of synthesizing IPD using information on a
covariate account for possible ecological bias and show a clear improvement in
accuracy over estimated treatment-covariate interactions, when compared to re-
sults obtained from synthesizing AD. CONCLUSIONS: Including evidence at IPD
level in the MTC is advisable when exploring participant level covariates; even
when IPD are only available for a fraction of the studies forming the evidence base.
Our findings suggest that adjusting for covariates impact produces intervention
effect estimates of higher accuracy, which is valuable for estimating subgroup
effects or adjusting for inconsistency.
PODIUM SESSION II:
DISCUSSION ON DECISIONS AND THE IMPACT OF NICE AND OTHER
REGULATORY BODIES IN THE UK
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OBJECTIVES: International health technology assessment is increasingly inter-
ested in the rapid review of technologies. In the UK NICE Single Technology Ap-
praisal (STA) process, manufacturers present the clinical and cost effectiveness of
new technologies in their evidence submissions. These submissions are critically
appraised by Evidence Review Groups (ERGs) who produce a report which forms
part of the evidence considered by the Appraisal Committees. Early on in the pro-
cess the ERG requests more information from the manufacturer via a clarification
letter. The purpose of this research was to analyse ERG reports and clarification
letters in order to develop guidance for manufacturers based on common problems
or issues identified in manufacturer submissions (MS). METHODS: A thematic
analysis of the first 30 completed ERG reports was undertaken using a framework
approach. Twenty one of the available associated clarification letters were anal-
ysed using a set of open codes to analyse data. Both sources of evidence were used
to identify common issues and concerns. RESULTS: Inadequate reporting of pro-
cesses was identified in 90% of reports; criticisms of data used, especially in the
model was mentioned for 67% of the reports and issues with the conduct of the
systematic review in 57%. The population and comparator represented the key
items in the decision problem assessed by the ERGs as being inadequately ad-
dressed by manufacturers. The majority of clarification points related to the eco-
nomic data analysis. Issues identified included clarification of data sources and
selection, queries about modelling decisions and requests for additional analyses.
Internal inconsistencies between the clinical and economic sections of the MS and
inconsistencies within the economic section of the MS were also identified as
particular problems. This analysis was used as the basis for the development of 12
recommendations for manufacturers. CONCLUSIONS: These recommendations
may help to improve the quality of manufacturers’ submissions.
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OBJECTIVES: Health technology assessments (HTAs) have the potential to influ-
ence the diffusion of medical devices into health care systems. This study investi-
gates the impact the National Institute for Health and Clinical Excellence’s (NICE)
technology appraisals have on the diffusion of implantable devices in the UK (UK).
METHODS: The analysis focused on the impact of NICE guidance on volume sold of
three medical devices: drug eluting stents (DES), implantable cardioverter defibril-
lators (ICD), and spinal cord stimulators (SCS). UK sales data (2005-2010) for each
device were collected from Eucomed and other industry sources. Diffusion pat-
terns before and after publication of NICE guidance were analyzed from an aggre-
gated market-level perspective. A linear regression model was fit to the time series
data to illustrate the relationship between the NICE decision and volume.
RESULTS: The results from the statistical analysis show that NICE guidance has
different effects on diffusion across products. NICE guidance had a step increase
impact in adoption of DES and SCS (p0.026 and p0.00, respectively).The model
suggests that the NICE review did not predict the diffusion of ICDs. Descriptive
analysis demonstrated that for SCS and ICDS the NICE decision had a positive effect
and no impact on DES diffusion on volume over time. Overall the units sold were
positively and significantly correlated with time post-NICE guidance.
CONCLUSIONS: The study indicates that NICE guidance influences the adoption of
medical devices. Positive recommendations were associated with an increase in
units sold despite a decrease in units sold experienced before the final recommen-
dation. Additionally, the analysis suggests that there may be a lag between a pos-
itive NICE decision and adoption of guidance recommendations in practice. Lastly,
there were no consistent trends on NICE’s effect on the rate of diffusion. More
research is needed to clearly understand the dynamics of HTAs on technology
adoption.
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ECONOMIC EVALUATION IN NICHE MARKETS: THE ROLE OF THE UK’S
ADVISORY GROUP FOR NATIONAL SPECIALISED SERVICES FOR RARE DISEASES
AND DISORDERS
Khan N1, Kiss N1, Pang F2
1Oxford Outcomes Ltd., Morristown, NJ, USA, 2Shire Human Genetic Therapies, Inc, Basingstoke,
UK
OBJECTIVES: The Advisory Group for National Specialised Services (AGNSS) is a
new committee that advises health ministers on which orphan services, including
orphan drugs, should be nationally commissioned. The aim of this paper is to
provide a description of AGNSS priorities, budget, and synergies with the National
Institute for Health and Clinical Excellence (NICE), and an analysis of the decision-
making framework used by AGNSS to recommend new drugs and technologies.
METHODS:A web-based search was conducted for articles and information related
to the specialized services of the National Health Service (NHS) and NICE. All doc-
uments, including AGNSS meeting minutes were analyzed to provide a compre-
hensive understanding of the AGNSS program. RESULTS: Beginning in 2010 and
each year thereafter, AGNSS will recommend approximately 60 highly specialized
services and a small number of new drugs and technologies that affect fewer than
500 patients in England. Drugs and stand-alone technologies first must be submit-
ted to NICE. Based on prevalence, disease severity, resource impact, and clinical
benefit, a subset of these are referred to AGNSS for consideration. AGNSS can
recommend “accept” or “accept with conditions” when the application meets the
quality, innovation, productivity, and prevention criteria, or will recommend to
“defer” or “reject” otherwise. Currently, AGNSS has identified eight priority areas
for 2011-2012. The total program budget in 2010/11, excluding three high-cost drugs
categories, is expected to be about £348 millions. Additionally, the planned budget
for high-cost drugs such as enzyme replacement therapy, paroxysymal nocturnal
hemoglobinuria (PNH), and cryopyrin-associated periodic syndromes (CAPS) is
£128,879, £27,592, and £3,080 million, respectively. CONCLUSIONS: Under the cur-
rent NHS framework, access to orphan drugs can be denied if they surpass NICE
implicit willingness to pay thresholds. The introduction of AGNSS offers an alter-
native evaluation mechanism, one that potentially offers the flexibility necessary
to comprehensively review orphan drugs and services.
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OBJECTIVES: To estimate the relationship between the maximum possible finan-
cial impact (MPFI) of a new medicine on the UK (UK) National Health Service (NHS)
and the probability of the drug being recommended for use in England and Wales
by the National Institute for Health and Clinical Excellence (NICE).METHODS:Data
were abstracted from the NICE guidance document and costing template for deci-
sions made about drugs between January 2001 and March 2011. MPFI was calcu-
lated by multiplying the population eligible for treatment with the new drug based
on the UK marketing indication by the upper bound estimate for the annual cost of
treatment. Descriptive, logistic, and recursive partitioning decision analyses were
used to estimate the relationship between the MPFI of a new medicine and the
probability of recommendation for use with or without restrictions. Multivariable
analyses controlled for other clinical and economic variables that have been shown
to be correlated with the probability of recommendation for use, including the cost
per quality-adjusted life-year (QALY) gained.RESULTS: In all analyses, MPFI was an
important predictor of the recommendation for use, in addition to cost per QALY.
In the univariate analysis, the mean MPFI was £140 million for medicines not
recommended and £92 million and £31 million for those recommended with and
without restrictions, respectively. In the logistic analysis, the coefficient on the
MPFI variable was statistically significant. In the recursive partitioning decision
analysis, the second split of the data for classifying recommendations, after cost
per QALY, was for submissions with an MPFI above or below £130 million.
CONCLUSIONS: In England and Wales, besides cost-effectiveness ratio, MPFI on
the NHS may be an important determinant of whether a new drug is recommended
for use with or without restrictions.
PODIUM SESSION II:
MERGING PRO AND UTILITY ASSESSMENT: DOES THE GAP INDEED GET
SMALLER?
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OBJECTIVES: To develop a method that enables estimation of a single value func-
tion using data from discrete choice (DC) and time trade off (TTO) questionnaires
and to analyse the informative value of an additional TTO question versus that of
an additional DC. METHODS: Separate DCE and TTO studies are designed with
varying numbers of health states (EQ-5D) to be valued. The DC states do not hold a
time dimension. An optimal Federov design is chosen for the TTO states, a Bayes-
ian approach is followed for the DC states. The base line is blocked design of 20
blocks with 10 DCE’s and 20 blocks of 5 TTO’s. Responses are simulated to both
study-types using prior expectations about answering behaviour, including 10% of
individuals who do not trade time when judging TTO states. Models are estimates
separately as well as simultaneously. For the latter all information is combined
using a likelihood approach assuming a generalised linear model underlying the
answers to the DC comparisons as well as to the TTO questions. The informative
value of adding an additional DC or TTO is measured by the average precision
surrounding the model parameters. RESULTS: While the TTO data offer sufficient
data to identify a value function, the DC data need normalizing constants. Com-
bining both approaches by estimating a single likelihood function takes care of this
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